BIA Separations, recently acquired by Sartorius, develops and manufactures market-leading CIM® monolithic chromatographic columns for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are applied in cell and gene therapies. BIA’s technology for manufacturing scale purification is already used in production of the first commercialized advanced therapeutics; BIA also has a keen presence with novel drug candidates in the clinical pipeline. Expecting continued strong double-digit sales growth over the next few years, BIA earned sales revenue approx. 25 million Euros in 2020, contributing to Sartorius Bioprocess Solutions, part of the Sartorius Group.
Precision NanoSystems (PNI) is a is a global leader in technologies and solutions for the development of genomic medicines, including mRNA vaccines and therapeutics. PNI enables the development of genomic medicines with a toolkit, including its proprietary GenVoyTM LNP delivery platform and NanoAssemblrTM microfluidic-based nanoparticle manufacturing platform, enabling rapid development of genomic medicines from research to clinic. PNI’s validated technologies increase stability, efficacy, yield, and quality of non-viral genomic medicines, and lowers the barrier to develop these important medicines.
ThermoFisher Scientific is a proven partner in the development and manufacture of nucleic acid therapeutics and mRNA vaccines. We offer a comprehensive product portfolio that spans the spectrum of nucleic acid therapeutic and vaccine development operations from early discovery to process development and commercial manufacturing.
Our expansive portfolio includes products and services for virtually every step involved in bringing a nucleic acid therapeutic or mRNA vaccine to the market including: target gene identification and optimization, gene synthesis, plasmid production and purification, in vitro transcription, mRNA purification, mRNA characterization, QC testing, and fill and finish capabilities..
Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
Merck is a leader in life science. We provide solutions to help you overcome your mRNA manufacturing and formulation challenges. With our broad portfolio of best-in-class products, our custom manufacturing capabilities and a wide range of services, we can support all stages of your mRNA drug manufacturing process. Discover how our capabilities, technical expertise and regulatory know-how can help you improve process economics, accelerate time to market and mitigate risks.
You want to scale and deliver your mRNA vaccines and therapeutics to the world quickly? We understand your goals and provide the solutions that will help you overcome your manufacturing challenges and meet your needs at all process steps.
eTheRNA immunotherapies is driving mRNA technology and therapeutic product development to deliver an innovative generation of RNA chemistries, RNA process technologies and a new and advanced generation of therapeutic and vaccine products. eTheRNA uses its established R&D foundations and in-house GMP manufacturing facilities and builds on its proprietary mRNA, mRNA adjuvant and mRNA formulation platforms to progress technology innovation and product development. eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology.
Codex DNA empowers researchers with the tools they need to rapidly and securely design, code, and create synthetic DNA. Creators of the BioXp™ system, the world’s only synthetic biology workstation, and the industry-standard Gibson Assembly® method, Codex DNA accelerates advances in the fields of personalized medicine, antibody engineering, vaccine development, biologics drug discovery, and more.
Founded in 2019, Arranta Bio is a visionary contract development and manufacturing organization (CDMO) that partners with companies seeking to develop and manufacture complex biological drugs and innovative therapies. Our dedicated team, state-of-the-art facilities, and unparalleled expertise are crucial for advancing products from development to commercial launch. Arranta Bio continues to expand capacity and development and manufacturing services across two sites with three distinct technology platforms designed to meet the evolving demands of our clients and partners.
TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap® mRNA capping technology. TriLink continues to expand its cGMP and general mRNA, oligonucleotide & plasmid manufacturing capacity at its new global headquarters in San Diego California, to support therapeutic, vaccine and diagnostic customers.
For nearly 30 years we have helped the world’s most innovative bio/pharmaceutical companies to navigate the challenges of new product development, drug delivery, production, and market release. We provide a broad range of cGMP, GLP, GCP laboratory services, with a focus on support for the development and production of mRNA, oligos, peptides, biologics, or vaccines. We are adept in establishing GMP validated analytical methods including mRNA specific methods such as integrity, potency, capping efficiency, sequencing, Poly(A) Tail, residual DNA template, residual dsRNA and delivery system testing (e.g. lipid nanoparticles (LNPs)). These comprehensive characterisation services provide data to determine protein expression and product purity, which can be directly linked to translation efficiency and immunogenicity. We also provide ICH stability and formulation development programs and have leading expertise in the product development of inhaled and nasal drugs.
Our outsourcing contracts are flexible and can be tailored to your specific timelines, requirements, and budgets.